{"id":"NCT00415194","sponsor":"Eli Lilly and Company","briefTitle":"A Study for Patients With Head and Neck Cancer","officialTitle":"A Randomized Phase 3 Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Monotherapy in Patients With Recurrent or Metastatic Head and Neck Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2010-03","completion":"2010-03","firstPosted":"2006-12-22","resultsPosted":"2011-04-06","lastUpdate":"2011-06-28"},"enrollment":795,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Head and Neck Neoplasms"],"interventions":[{"type":"DRUG","name":"pemetrexed","otherNames":["Alimta","LY231514"]},{"type":"DRUG","name":"cisplatin","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Pemetrexed/Cisplatin","type":"EXPERIMENTAL"},{"label":"Placebo/Cisplatin","type":"PLACEBO_COMPARATOR"}],"summary":"This study will compare the effects of pemetrexed plus cisplatin versus cisplatin alone in head and neck cancer patients.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Baseline to date of death from any cause up to 36 months","effectByArm":[{"arm":"Pemetrexed/Cisplatin","deltaMin":7.33,"sd":null},{"arm":"Placebo/Cisplatin","deltaMin":6.28,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.082"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":94,"countries":["United States","Argentina","Belgium","Brazil","China","Denmark","France","Germany","Hungary","India","Italy","Mexico","Netherlands","Poland","Puerto Rico","Romania","Russia","South Africa","South Korea","Spain","Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":185,"n":392},"commonTop":["Nausea","Anaemia","Vomiting","Fatigue","Constipation"]}}